Expression of Particulate-form of Japanese Encephalitis Virus Envelope Protein in a Stably Transfected Drosophila Cell Line
Overview
Affiliations
Background: Japanese encephalitis virus (JEV), a member of the family Flaviviridae, is an important mosquito-borne human pathogen. Its envelope glycoprotein (E) is the major determinant of the pathogenicity and host immune responses. In the present study, we explored the feasibility of producing recombinant JEV E protein in the virus-free Drosophila expression system.
Results: The coding sequence for the signal sequence of premembrane and E protein was cloned into the Drosophila expression vector pAc5.1/V5-His. A Drosophila cell line S2 was cotransfected with this construct as well as a plasmid providing hygromycin B resistance. A cell line expressing the JEV E protein was selected by immunofluoresence, confocal microscopy, and western blot analysis using three different monoclonal antibodies directed against JEV E protein. This cell line was stable in the yield of JEV E protein during two months in vitro maintenance in the presence of hygromycin B. The results showed that the recombinant E protein had an expected molecular weight of about 50 kilodalton, was immunoreactive with all three monoclonal antibodies, and found in both the cytoplasm and culture supernatant. Sucrose gradient ultracentrifugation analysis revealed that the secreted E protein product was in a particulate form. It migrated to the sucrose fraction with a density of 1.13 g/ml. Balb/c mice immunised with the sucrose fraction containing the E protein particles developed specific antibodies. These data show that functioning JEV E protein was expressed in the stable S2 cell line.
Conclusion: The Drosophila expression system is a more convenient, cheaper and safer approach to the production of vaccine candidates and diagnostic reagents for JEV.
Virus-Like Particle Systems for Vaccine Development against Viruses in the Flaviviridae Family.
Wong S, Jassey A, Wang J, Wang W, Liu C, Lin L Vaccines (Basel). 2019; 7(4).
PMID: 31547131 PMC: 6963367. DOI: 10.3390/vaccines7040123.
Matsuda S, Nerome R, Maegawa K, Kotaki A, Sugita S, Kawasaki K Heliyon. 2017; 3(4):e00286.
PMID: 28435908 PMC: 5390689. DOI: 10.1016/j.heliyon.2017.e00286.
Garcia-Machorro J, Lopez-Gonzalez M, Barrios-Rojas O, Fernandez-Pomares C, Sandoval-Montes C, Santos-Argumedo L Hum Vaccin Immunother. 2013; 9(11):2326-35.
PMID: 23880886 PMC: 3981841. DOI: 10.4161/hv.25673.
Astray R, Jorge S, Lemos M, Yokomizo A, Boldorini V, Puglia A Cytotechnology. 2013; 65(5):829-38.
PMID: 23340966 PMC: 3967614. DOI: 10.1007/s10616-012-9522-6.
Development of a vaccine to prevent Japanese encephalitis: a brief review.
Wiwanitkit V Int J Gen Med. 2010; 2:195-200.
PMID: 20360904 PMC: 2840557. DOI: 10.2147/ijgm.s6281.